Exciting developments in the fight against HIV are emerging from two new mRNA vaccine trials, which show promise in overcoming the virus’s elusive nature. HIV has long stumped scientists due to its highly varied strains—making broad immunity difficult—and its ability to evade the immune system. However, early trial results hint at the potential for a single-dose vaccine that triggers a wide-ranging immune response. While some participants experienced skin reactions and a viable vaccine remains years away, the progress is encouraging. Coupled with the recent approval of lenacapavir, a preventative HIV drug that requires just two injections a year, these breakthroughs mark a hopeful turning point in the decades-long battle against AIDS.
SEMAFOR
